RECURRENT FALLOPIAN TUBE CARCINOMA
Clinical trials for RECURRENT FALLOPIAN TUBE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT FALLOPIAN TUBE CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT FALLOPIAN TUBE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy and chemotherapy join forces to fight recurrent ovarian cancer
Disease control CompletedThis phase II trial tests whether combining the immunotherapy drug pembrolizumab (Keytruda) with the chemotherapy drug carboplatin can prevent ovarian, fallopian tube, or primary peritoneal cancer from progressing after a blood test shows it may have returned. The study includes …
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug cocktail targets Hard-to-Treat ovarian and endometrial cancers
Disease control CompletedThis early-stage trial tested two drugs—niraparib and copanlisib—in 31 people with recurrent endometrial, ovarian, peritoneal, or fallopian tube cancer. The goal was to find the safest dose and see how well patients tolerated the combination. Both drugs work by blocking enzymes t…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a custom vaccine help fight ovarian cancer?
Disease control CompletedThis early-phase trial tested a personalized vaccine made from a patient's own immune cells to see if it is safe for people with advanced ovarian, fallopian tube, or peritoneal cancer. Nineteen participants who had already undergone surgery and chemotherapy received the vaccine. …
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: EARLY_PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug combo shows promise for resistant ovarian cancer
Disease control CompletedThis study tested a new drug called relacorilant combined with chemotherapy (nab-paclitaxel) in 178 women with ovarian, fallopian tube, or peritoneal cancer that came back and no longer responds to platinum-based treatments. The goal was to see if the combination helps keep the c…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Immunotherapy combo shows promise for Hard-to-Treat ovarian cancer
Disease control CompletedThis phase II trial tested two immunotherapy drugs, durvalumab and tremelimumab, in 100 women with ovarian, fallopian tube, or peritoneal cancer that had come back or stopped responding to platinum-based chemotherapy. The study compared giving the drugs together versus one after …
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 26, 2026 19:06 UTC
-
Targeted radiation shows promise for recurrent gynecologic cancers
Symptom relief CompletedThis early-phase study tested a precise type of radiation called stereotactic body radiation therapy (SBRT) in 15 women whose ovarian or uterine cancer had come back in a limited area. The main goal was to find the safest dose and check for side effects. Researchers also looked a…
Matched conditions: RECURRENT FALLOPIAN TUBE CARCINOMA
Phase: PHASE1 • Sponsor: University of Colorado, Denver • Aim: Symptom relief
Last updated Jun 27, 2026 07:55 UTC